# Selinexor in Patients With Advanced Thymic Epithelial Tumor Progressing After Primary Chemotherapy

> **NCT03193437** · PHASE2 · TERMINATED · sponsor: **Georgetown University** · enrollment: 8 (actual)

## Conditions studied

- Thymoma
- Advanced Thymic Epithelial Tumor

## Interventions

- **DRUG:** Open Label Selinexor

## Key facts

- **NCT ID:** NCT03193437
- **Lead sponsor:** Georgetown University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-04-03
- **Primary completion:** 2020-07-27
- **Final completion:** 2022-01-31
- **Target enrollment:** 8 (ACTUAL)
- **Why stopped:** Slow Accrual
- **Last updated:** 2023-02-16

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03193437

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03193437, "Selinexor in Patients With Advanced Thymic Epithelial Tumor Progressing After Primary Chemotherapy". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03193437. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*